Schering-Plough to acquire Organon BioSciences

Share this article:
Schering-Plough announced that it will acquire Organon BioSciences, the human and animal health care business of Netherlands-based Akzo Nobel, in a deal valued at $14.4 billion. The transaction is expected to close by the end of 2007. Organon’s pharmaceutical business had sales of $3.4 billion in 2006, fueled by sales of Follistim/Puregon, a follicle stimulating hormone for infertility; Esmeron/Zemuron, a muscle relaxant and NuvaRing and Implanon for contraception. Organon’s Intervet animal health business had sales of $1.5 billion in 2006. Organon currently has five pharmaceutical compounds in phase III development, including agents for the treatment of schizophrenia and bipolar disorder, surgically induced neuromuscular blockade, infertility and an oral contraceptive. Under the deal, Organon’s R&D facility in Oss, the Netherlands, will become the center of Schering-Plough’s global gynecology and fertility activities, while Organon’s neuroscience research will continue in Newhouse, Scotland, Schering-Plough said in a news release.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...